Crinetics Pharmaceuticals, Inc.

Not even two months into the new year and some of the expected biggest-earning new drugs of 2025 have already been approved. An updated analysis conducted by Scrip and Evaluate Pharma of drugs expec

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Neurocrine Biosciences will soon launch its second wholly owned commercial product, Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH), adding what the company sees as another

The number of biopharmaceutical companies that have gone public in the US in 2024 has now beat the 2023 total of 21 with the 10 October initial public offerings by Upstream Bio Inc. and CAMP4 Thera